Chrysopogon zizanioides VOLATILE COMPOUNDS AS POTENTIAL INHALED THERAPEUTICS FOR METASTATIC LUSC BIOMARKER
DOI:
https://doi.org/10.36526/biosense.v9i3.8222Keywords:
Chrysopogon zizaioides, Lung squamous carcinoma, Metastatic, Volatile compoundsAbstract
Lung squamous cell carcinoma (LUSC) remains a major subtype of non-small cell lung cancer with limited therapeutic options, particularly in metastatic stages. This study aimed to identify extracellular matrix (ECM)-associated biomarkers involved in LUSC progression and evaluate volatile compounds from Chrysopogon zizanioides as potential inhaled therapeutic candidates through an integrated computational approach. Gene expression and survival analysis were performed using UALCAN and TNMplot databases to identify prognostic ECM-related biomarkers. Volatile compounds of C. zizanioides were screened using drug-likeness and toxicity prediction analysis. Molecular docking was subsequently conducted against representative COL6A3 domains, including the N2 domain, Kunitz-associated domain, and microfibrillar structure. Pharmacokinetic (PK) properties relevant to inhalation-based therapy were also assessed. The results demonstrated that COL6A3 was significantly overexpressed in tumor and metastatic LUSC tissues and associated with poor overall survival trends, suggesting its involvement in tumor microenvironment remodeling and metastatic progression. Among 30 identified volatile compounds, zizanal and khusitone exhibited favorable drug-likeness and low predicted toxicity profiles. Whole-protein and specific-site molecular docking analyses revealed that both compounds showed stronger binding affinities toward the microfibrillar region of COL6A3 than pirfenidone, with khusitone demonstrating the strongest interaction (-7.12 kcal/mol). Interaction analysis identified ARG2811 as a key residue contributing to ligand stabilization. Furthermore, PK prediction suggested favorable pulmonary-oriented characteristics, including efficient membrane permeability, low CYP450 interaction risk, reduced blood-brain barrier penetration, and moderate plasma clearance. Collectively, these findings suggest that zizanal and khusitone may serve as promising lead compounds for inhaled therapeutics targeting COL6A3-associated metastatic LUSC.
References
Abd El-Salam, M., Chen, W., Tang, Y., Rao, T., Kang, X., Sun, L., … Pan, C.-X. (2026). Synergistic effects through targeting the PI3K and IGFR pathways in treating lung cancer carrying activation alterations along the PI3K pathway. Translational Oncology, 67, 102753. https://doi.org/10.1016/j.tranon.2026.102753
Afendi, F. M., Okada, T., Yamazaki, M., Hirai-Morita, A., Nakamura, Y., Nakamura, K., … Kanaya, S. (2012). KNApSAcK Family Databases: Integrated Metabolite–Plant Species Databases for Multifaceted Plant Research. Plant and Cell Physiology, 53(2), e1–e1. https://doi.org/10.1093/pcp/pcr165
Alam, K., Crowe, A., Wang, X., Zhang, P., Ding, K., Li, L., & Yue, W. (2018). Regulation of Organic Anion Transporting Polypeptides (OATP) 1B1- and OATP1B3-Mediated Transport: An Updated Review in the Context of OATP-Mediated Drug-Drug Interactions. International Journal of Molecular Sciences, 19(3), 855. https://doi.org/10.3390/ijms19030855
Alduais, Y., Zhang, H., Fan, F., Chen, J., & Chen, B. (2023). Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment. Medicine, 102(8), e32899. https://doi.org/10.1097/MD.0000000000032899
Anderson, S., Atkins, P., Bäckman, P., Cipolla, D., Clark, A., Daviskas, E., … Weers, J. (2022). Inhaled Medicines: Past, Present, and Future. Pharmacological Reviews, 74(1), 48–118. https://doi.org/10.1124/pharmrev.120.000108
Banerjee, P., Kemmler, E., Dunkel, M., & Preissner, R. (2024). ProTox 3.0: A webserver for the prediction of toxicity of chemicals. Nucleic Acids Research, 52(W1), W513–W520. https://doi.org/10.1093/nar/gkae303
Benitez, D. A., Cumplido-Laso, G., Olivera-Gómez, M., Del Valle-Del Pino, N., Díaz-Pizarro, A., Mulero-Navarro, S., … Carvajal-Gonzalez, J. M. (2024). p53 Genetics and Biology in Lung Carcinomas: Insights, Implications and Clinical Applications. Biomedicines, 12(7), 1453. https://doi.org/10.3390/biomedicines12071453
Bowie, J. U., LtCY, R., & Eisenberg, D. (1991). A Method to Identify Protein Sequences That Fold into a Known Three-Dimensional Stucture. 253.
Catani, G., Morchón-Araujo, D., Mirallas, O., Sánchez-Pérez, V., Nuciforo, P., Villacampa, G., … Hernando-Calvo, A. (2025). Optimizing early-phase immunotherapy trials: The role of biomarker enrichment strategies. Frontiers in Immunology, 16, 1664443. https://doi.org/10.3389/fimmu.2025.1664443
Chandrashekar, D. S., Bashel, B., Balasubramanya, S. A. H., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B. V. S. K., & Varambally, S. (2017). UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia, 19(8), 649–658. https://doi.org/10.1016/j.neo.2017.05.002
Chen, H., Zheng, S., Pan, Y., Li, Y., Cheng, C., Shen, X., … Wang, R. (2015). SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas. OncoTargets and Therapy, 3009. https://doi.org/10.2147/OTT.S91293
Colovos, C., & Yeates, T. O. (1993). Verification of protein structures: Patterns of nonbonded atomic interactions. Protein Science, 2(9), 1511–1519. https://doi.org/10.1002/pro.5560020916
Deodhar, M., Al Rihani, S. B., Arwood, M. J., Darakjian, L., Dow, P., Turgeon, J., & Michaud, V. (2020). Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice. Pharmaceutics, 12(9), 846. https://doi.org/10.3390/pharmaceutics12090846
Duan, Y., Liu, G., Sun, Y., Wu, J., Xiong, Z., Jin, T., & Chen, M. (2019). COL6A3 polymorphisms were associated with lung cancer risk in a Chinese population. Respiratory Research, 20(1), 143. https://doi.org/10.1186/s12931-019-1114-y
Faisal, M., & Hariaji, I. (2026). DNA-3-METHYLADENINE GLYCOSYLASE AS CANCER TARGET PROTEIN OF GOSSYPOL DERIVATIVES: A COMPUTATIONAL PHARMACOLOGY ANALYSIS. 9(1).
Gunasekar, C. J., Majdalawieh, A. F., Abu-Yousef, I. A., & Al Refaai, S. A. (2025). Pharmacological and Therapeutic Potential of Chrysopogon zizanioides (Vetiver): A Comprehensive Review of Its Medicinal Applications and Future Prospects. Biomolecules, 15(9), 1312. https://doi.org/10.3390/biom15091312
Guo, Y., Bera, H., Shi, C., Zhang, L., Cun, D., & Yang, M. (2021). Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines. Acta Pharmaceutica Sinica B, 11(8), 2565–2584. https://doi.org/10.1016/j.apsb.2021.05.015
Huang, Y., Li, G., Wang, K., Mu, Z., Xie, Q., Qu, H., … Hu, B. (2018). Collagen Type VI Alpha 3 Chain Promotes Epithelial-Mesenchymal Transition in Bladder Cancer Cells via Transforming Growth Factor β (TGF-β)/Smad Pathway. Medical Science Monitor, 24, 5346–5354. https://doi.org/10.12659/MSM.909811
Iyengar, P., Espina, V., Williams, T. W., Lin, Y., Berry, D., Jelicks, L. A., … Scherer, P. E. (2005). Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. Journal of Clinical Investigation, 115(5), 1163–1176. https://doi.org/10.1172/JCI23424
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993). PROCHECK: A program to check the stereochemical quality of protein structures. Journal of Applied Crystallography, 26(2), 283–291. https://doi.org/10.1107/S0021889892009944
Lee, J. J., Ng, K. Y., & Bakhtiar, A. (2025). Extracellular matrix: Unlocking new avenues in cancer treatment. Biomarker Research, 13(1), 78. https://doi.org/10.1186/s40364-025-00757-3
Lingo, J. J., Balas, M. M., Scherer, P. E., & Klein, J. C. (2025). The Role of COL6A3 in Tumorigenesis, Metastasis, Diagnosis, and Disease Management. Cancers, 17(21), 3449. https://doi.org/10.3390/cancers17213449
Ma, S., Zhao, N., Dong, X., Wang, Y., Song, L., Zheng, R., … Xiao, T. (2025). Liquid biopsy-derived extracellular vesicle protein biomarkers for diagnosis and prognostic assessment of lung squamous cell carcinoma. Cancer Cell International, 25(161). https://doi.org/https://doi.org/10.1186/s12935-025-03792-0
Marques, L., & Vale, N. (2022). Salbutamol in the Management of Asthma: A Review. International Journal of Molecular Sciences, 23(22), 14207. https://doi.org/10.3390/ijms232214207
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. https://doi.org/10.1002/jcc.21256
Neves, M. A. C., Yeager, M., & Abagyan, R. (2012). Unusual Arginine Formations in Protein Function and Assembly: Rings, Strings, and Stacks. The Journal of Physical Chemistry B, 116(23), 7006–7013. https://doi.org/10.1021/jp3009699
Peng, C., Kong, X., Hui, Y., Yang, X., Hou, Y., Sheng, W., … Yu, W. (2025). FAM83A is a prognostic biomarker for lung squamous cell carcinoma and correlated with immunoregulation. Scientific Reports, 15(1), 36590. https://doi.org/10.1038/s41598-025-20417-8
Reifs, A., Fernandez-Calvo, A., Alonso-Lerma, B., Schönfelder, J., Franco, D., Ortega-Muñoz, M., … Perez-Jimenez, R. (2024). High-throughput virtual search of small molecules for controlling the mechanical stability of human CD4. Journal of Biological Chemistry, 300(4), 107133. https://doi.org/10.1016/j.jbc.2024.107133
Zanoaga, O., Braicu, C., Nutu, A., Berindan-Neagoe, I., & Bender, A. (2026). The role of the tumor microenvironment in drug resistance acquisition in lung squamous cell carcinoma. Journal of Experimental & Clinical Cancer Research, 45(1), 95. https://doi.org/10.1186/s13046-026-03682-x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 JURNAL BIOSENSE
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
